Cargando…

Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial

OBJECTIVE: To assess the impact of maintenance nifedipine therapy on pregnancy duration in women with preterm placenta previa bleeding. METHODS: PPADAL was a randomized, double-blind, placebo-controlled trial conducted between 05/2008 and 05/2012 in five French hospitals. The trial included 109 wome...

Descripción completa

Detalles Bibliográficos
Autores principales: Verspyck, Eric, de Vienne, Claire, Muszynski, Charles, Bubenheim, Michael, Chanavaz-Lacheray, Isabella, Dreyfus, Michel, Deruelle, Philippe, Benichou, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363821/
https://www.ncbi.nlm.nih.gov/pubmed/28333939
http://dx.doi.org/10.1371/journal.pone.0173717
_version_ 1782517214929223680
author Verspyck, Eric
de Vienne, Claire
Muszynski, Charles
Bubenheim, Michael
Chanavaz-Lacheray, Isabella
Dreyfus, Michel
Deruelle, Philippe
Benichou, Jacques
author_facet Verspyck, Eric
de Vienne, Claire
Muszynski, Charles
Bubenheim, Michael
Chanavaz-Lacheray, Isabella
Dreyfus, Michel
Deruelle, Philippe
Benichou, Jacques
author_sort Verspyck, Eric
collection PubMed
description OBJECTIVE: To assess the impact of maintenance nifedipine therapy on pregnancy duration in women with preterm placenta previa bleeding. METHODS: PPADAL was a randomized, double-blind, placebo-controlled trial conducted between 05/2008 and 05/2012 in five French hospitals. The trial included 109 women, aged ≥ 18 years, with at least one episode of placenta previa bleeding, intact membranes and no other pregnancy complication, at gestational age 24 to 34 weeks and after 48 hours of complete acute tocolysis. Women were randomly allocated to receive either 20 mg of slow-release nifedipine three times daily (n = 54) or placebo (n = 55) until 36 + 6 weeks of gestation. The primary outcome for the trial was length of pregnancy measured in days after enrolment. Main secondary outcomes were rates of recurrent bleeding, cesarean delivery due to hemorrhage, blood transfusion, maternal side effects, gestational age at delivery and adverse perinatal outcomes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage > grade 2, perventricular leukomalacia > grade 1, or necrotizing enterocolitis). Analysis was by intention to treat. RESULTS: Mean (SD) prolongation of pregnancy was not different between the nifedipine (n = 54) and the placebo (n = 55) group; 42.5 days ± 23.8 versus 44.2 days ± 24.5, p = 0.70. Cesarean due to hemorrhage performed before 37 weeks occurred more frequently in the nifedipine group in comparison with the placebo group (RR, 1.66; 95% confidence interval, 1.05–2.72). Adverse perinatal outcomes were comparable between groups; 3.8% for nifedipine versus 5.5% for placebo (relative risk, 0.52; 95% confidence interval 0.10–2.61). No maternal mortality or perinatal death occurred. CONCLUSION: Maintenance oral nifedipine neither prolongs duration of pregnancy nor improves maternal or perinatal outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00620724
format Online
Article
Text
id pubmed-5363821
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53638212017-04-06 Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial Verspyck, Eric de Vienne, Claire Muszynski, Charles Bubenheim, Michael Chanavaz-Lacheray, Isabella Dreyfus, Michel Deruelle, Philippe Benichou, Jacques PLoS One Research Article OBJECTIVE: To assess the impact of maintenance nifedipine therapy on pregnancy duration in women with preterm placenta previa bleeding. METHODS: PPADAL was a randomized, double-blind, placebo-controlled trial conducted between 05/2008 and 05/2012 in five French hospitals. The trial included 109 women, aged ≥ 18 years, with at least one episode of placenta previa bleeding, intact membranes and no other pregnancy complication, at gestational age 24 to 34 weeks and after 48 hours of complete acute tocolysis. Women were randomly allocated to receive either 20 mg of slow-release nifedipine three times daily (n = 54) or placebo (n = 55) until 36 + 6 weeks of gestation. The primary outcome for the trial was length of pregnancy measured in days after enrolment. Main secondary outcomes were rates of recurrent bleeding, cesarean delivery due to hemorrhage, blood transfusion, maternal side effects, gestational age at delivery and adverse perinatal outcomes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage > grade 2, perventricular leukomalacia > grade 1, or necrotizing enterocolitis). Analysis was by intention to treat. RESULTS: Mean (SD) prolongation of pregnancy was not different between the nifedipine (n = 54) and the placebo (n = 55) group; 42.5 days ± 23.8 versus 44.2 days ± 24.5, p = 0.70. Cesarean due to hemorrhage performed before 37 weeks occurred more frequently in the nifedipine group in comparison with the placebo group (RR, 1.66; 95% confidence interval, 1.05–2.72). Adverse perinatal outcomes were comparable between groups; 3.8% for nifedipine versus 5.5% for placebo (relative risk, 0.52; 95% confidence interval 0.10–2.61). No maternal mortality or perinatal death occurred. CONCLUSION: Maintenance oral nifedipine neither prolongs duration of pregnancy nor improves maternal or perinatal outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00620724 Public Library of Science 2017-03-23 /pmc/articles/PMC5363821/ /pubmed/28333939 http://dx.doi.org/10.1371/journal.pone.0173717 Text en © 2017 Verspyck et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Verspyck, Eric
de Vienne, Claire
Muszynski, Charles
Bubenheim, Michael
Chanavaz-Lacheray, Isabella
Dreyfus, Michel
Deruelle, Philippe
Benichou, Jacques
Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title_full Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title_fullStr Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title_full_unstemmed Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title_short Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
title_sort maintenance nifedipine therapy for preterm symptomatic placenta previa: a randomized, multicenter, double-blind, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363821/
https://www.ncbi.nlm.nih.gov/pubmed/28333939
http://dx.doi.org/10.1371/journal.pone.0173717
work_keys_str_mv AT verspyckeric maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT devienneclaire maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT muszynskicharles maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT bubenheimmichael maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT chanavazlacherayisabella maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT dreyfusmichel maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT deruellephilippe maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT benichoujacques maintenancenifedipinetherapyforpretermsymptomaticplacentapreviaarandomizedmulticenterdoubleblindplacebocontrolledtrial